Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
220.1 CHF | -0.63% | -1.92% | -9.98% |
Apr. 17 | Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial | MT |
Apr. 17 | Roche: positive phase III results in MS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.98% | 194B | |
+28.79% | 676B | |
+24.81% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+2.47% | 210B | |
-0.02% | 204B | |
-11.71% | 144B | |
-8.32% | 142B |
- Stock Market
- Equities
- ROG Stock
- News Roche Holding AG
- Roche : To Continue Developing COVID-19 Therapies, Diagnostics Amid Endemic Possibility